Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Immunotherapy With Glatiramer Acetate in PLWHIV in Poor Immunological Responders on Antiretroviral Therapy (GEODE)

25 de septiembre de 2026 actualizado por: ANRS, Emerging Infectious Diseases

Immunotherapy With Glatiramer Acetate in PLWHIV in Poor Immunological Responders on Antiretroviral Therapy: a Phase II, Multicenter, Randomized, Open-label, Pilot Clinical Trial

The purpose of this trial is to evaluate the immunomodulatory effects of glatiramer acetate (GA) in improving the recovery of CD4 T cells and the CD4/CD8 ratio in people living with HIV (PLWHIV) who have poor immune recovery and persistent immune activation, despite virologically effective antiretroviral (ARV) treatment.

ANRS 0766s GEODE is a Pilot, multicenter, randomised and open-label clinical trial:

Participants will be randomized 2:1 to either one of the two parallel arms

  • Arm A (24 participants) : Glatiramer Acetate (GA)
  • Arms B (12 participants) : control

Randomisation of the trial arms:

The participants will be randomised in an open-label trial in a 2:1 ratio with, for each arm, a distribution by age group (< 50 and = or > 50 years) using a minimisation randomisation method.

The trial will consist of three phases:

Phase I: A first controlled phase in which participants in arm A will receive subcutaneous injections of GA three times a week for 16 weeks, and will be compared with participants randomised to arm B who do not receive GA (control group). The primary endpoint will be assessed at week 16 (end of the controlled phase).

Phase II: A second post-interventional observational phase will begin after W16 to evaluate a potential post-treatment effect and its duration in arm A.

During this phase, the efficacy of the strategy during the phase I will be analysed for all participants (once the last randomised participant has reached week 16).

It will continue until the potential opening of the phase III extension, in the event of efficacy be confirmed, or until the decision to terminate the trial if this is not the case.

Phase III: An optional third extension phase may be offered to participants in both arms. The opening of this phase will be conditional upon prior demonstration of a global benefit between both treatment groups during Phase I. During this optional phase III, participants in arm A will be offered a second cycle of GA and those in arm B, a first cycle of GA at the same frequency as a subcutaneous injection three times a week for 16 weeks. Participation in this phase will be optional.

All participants will continue their current antiretroviral treatment.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

36

Fase

  • Fase 2

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Âge > or = to 18 years,
  • HIV-1 infection,
  • Receiving ART,
  • Have a sustained HIV-1 plasma viral load <50 copies/mL on ART for more than 3 years (blips <400 copies/mL allowed),
  • Have a blood CD4 T cell count <500 cells/μL (at the last three time points analyzed, including the screening visit, in the 18 months),
  • Have a blood CD4/CD8 T cell ratio <0.5 (at the last three time points analyzed, including the screening visit, in the past 18 months),
  • Willing to receive treatment via subcutaneous injections three times a week, to adhere to the study schedule, and to accept blood samples in accordance with the protocol,
  • Informed and written consent signed by the participant and the investigator (no later than the day of the enrolment visit and prior to any examination to be carried out as part of the trial) (Article L1122-1-1 of the Public Health Code),
  • Participant covered by health insurance (Article L1121-11 of the Public Health Code).

Exclusion Criteria:

  • HIV-2 infection,
  • Age >65 years (to avoid lack of immune reconstitution due to immunosenescence),
  • Hypersensitivity to glatiramer acetate or to its excipient: mannitol,
  • Current treatment with systemic corticosteroids, or during the 12 weeks prior to randomisation,
  • Current treatment with immunosuppressants, or during the 12 weeks prior to randomisation,
  • History of chemotherapy or radiation therapy (any date),
  • History of hematologic disorders (e.g. lymphoma, leukemia, Bone marrow transplant, solid organ transplant),
  • History of cancer (except cancer that was cured by surgery alone more than 5 years ago; cutaneous epidermoid carcinoma; carcinoma in situ; Kaposi sarcoma that resolved without chemotherapy or radiation therapy),
  • Chronic hepatitis B (positive HBs antigen) or hepatitis C (positive HCV RNA); cirrhosis (including non-viral causes),
  • Active opportunistic infections with risk of severe immune reconstitution inflammatory syndrome (tuberculous neuromeningitis or cryptococcal neuromeningitis),
  • Pregnancy or intention to be pregnant during the study period
  • Participation in any other clinical trial of an investigational agent or in any interventional or non-interventional study requiring additional blood sampling. Participation in an observational study without additional blood sampling is permitted.
  • Participants under guardianship or curatorship or under judicial protection,
  • Renal failure : eGFR < 30 mL/min/1.73 m² (CKD-EPI formula)

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Arm A (24 participants) : GLATIRAMER VIATRIS 40mg/ml

Participants will receive GA via subcutaneous injections (40 mg/ml), three times a week, for 16 weeks in addition to their current antiretroviral treatment.

Participants will receive GA via subcutaneous injections (40 mg/ml), three times a week, for 16 weeks in addition to their current antiretroviral treatment. The first injection will be administered in hospital under medical supervision. Subsequent injections will be self-administered by participants at home. An injection pen to facilitate subcutaneous injections will be provided to participants.

Sin intervención: Arms B (12 participants) : control

Control group (Arm B): The participants will continue their current antiretroviral treatment.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in the CD4/CD8 ratio between W0 and W16 (intra-patient difference between the CD4/CD8 ratio at Week16 and Week0).
Periodo de tiempo: 16Weeks

Change in the CD4/CD8 ratio between Week0 and Week16 (intra-patient difference between the CD4/CD8 ratio at Week16 and Week0).

16Weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de diciembre de 2026

Finalización primaria (Estimado)

15 de diciembre de 2028

Finalización del estudio (Estimado)

15 de diciembre de 2030

Fechas de registro del estudio

Enviado por primera vez

1 de septiembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

25 de septiembre de 2026

Publicado por primera vez (Actual)

1 de octubre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

1 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

25 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • ANRS 0766s GEODE

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .